NanoSphere Health Sciences Inc.
NSHSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -5.20 | 0.01 | 0.01 | 0.07 |
| FCF Yield | -12.48% | -209.05% | -59.86% | -4.71% |
| EV / EBITDA | 1.25 | -1.34 | -0.21 | -3.64 |
| Quality | ||||
| ROIC | 14.22% | 14.13% | 20.05% | 33.01% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.14 | 0.24 | 0.24 | 0.18 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 33.12% | 20.63% | -4.61% | -36.87% |
| Safety | ||||
| Net Debt / EBITDA | 0.11 | 0.76 | 0.20 | 0.38 |
| Interest Coverage | -94.42 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |